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OSRx, particularly in those women diagnosed with osteopenia
and/or osteoporosis according to their test results.
POS2
DIFFERENCES BETWEEN DOCTOR AND PATIENT RECALL OF
EVENTS IN AND INVESTIGATIONS FOR OSTEOPOROSIS IN
FIVE COUNTRIES
Piercy J1,Tompkins R2, Kay S2, Karavali M2
1Adelphi Group, Macclesﬁeld, Cheshire, United Kingdom; 2Adelphi
Group Products, Macclesﬁeld, Cheshire, United Kingdom
OBJECTIVES: Patients and physicians are sometimes asked to
ﬁll in questionnaires concerning clinical events and resource util-
isation such as tests and investigations. This study analyses dif-
ferences in reporting of diagnostic tests and clinical events by a
matched sample of doctors and patients in the management of
osteoporosis in ﬁve countries. METHODS: The data are drawn
from the Disease Speciﬁc Programme in Osteoporosis, which col-
lected information about osteoporosis management from both
doctors and patients. The study included 7349 patients (aged
50–80 with osteoporosis or suspected osteoporosis), treated by
709 doctors in France, UK, Germany, Italy, USA. For each doctor
record, patients were asked to ﬁll out a self-completion ques-
tionnaire. 2646 matched patient self-completion records were
obtained. Key data items collected from both doctors and
patients were X-rays, bone mineral density (BMD) scanning, and
fractures. Differences between matched physician and patient
responses were tested using the Fisher Exact test. RESULTS:
Patients were signiﬁcantly more likely to recall X-rays than
doctors (41.2% vs. 33.8%, p < 0.01). This difference was sig-
niﬁcant in each country except Italy and Germany, although
patients still reported higher levels of testing. No signiﬁcant dif-
ferences were found for BMD scanning other than the UK, where
patients reported a higher level of testing (65.0% vs. 44.0%, 
p < 0.01). Patients were less likely to report fractures (30.0% vs.
36.4%, p < 0.01). Statistically signiﬁcant differences were
observed in all countries except the USA. CONCLUSIONS: This
study demonstrates differences between physicians and patients
in terms of both resource use and events. Patients reported more
tests but less fractures than doctors. These ﬁndings have impli-
cations for economic evaluations. Evidence from patients must
be treated with caution, due to potential problems of recall bias
and/or misunderstanding of tests and events. The importance 
of using hard evidence for retrospective analysis cannot be 
overstated.
OSTEOPOROSIS
OSTEOPOROSIS—Cost Studies
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HEALTH CARE UTILIZATION AND EXPENDITURES: A STUDY
OF SEVERE OSTEOPOROSIS
Orsini LS1, Long S2, Pantos B3,Wang S1, Rousculp M3
1The Medstat Group, Inc, Cambridge, MA, USA; 2Medstat,
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OBJECTIVE: More than 1.5 million fractures occur due to
osteoporosis each year. This study examines the characteristics
of osteoporosis patients who incur an osteoporosis-related frac-
ture compared to osteoporosis patients who do not incur frac-
ture and estimates the economic burden associated with the
illness. METHODS: The study sample consisted of patients with
an osteoporosis diagnosis (733.0x) between January 1, 1998 and
December 31, 2000. Osteoporosis patients with both an osteo-
porosis diagnosis and a related fracture were classiﬁed as having
severe osteoporosis, all other osteoporosis patients were classi-
ﬁed as Non-Severe. Annual utilization and expenditures for the
Severe cohort were compared to the Non-severe cohort, as well
as to a group of patients without osteoporosis (Controls)
matched 3 :1 to the Severe osteoporosis cohort based on age,
gender, region, health plan type, and length of enrollment.
Patients with malignant neoplasm, carcinoma, or Paget’s disease
of bone were excluded from all groups. Exponential conditional
mean models were used to compute regression-adjusted total
expenditures across the groups and the differences in adjusted
expenditures were used to generate the economic burden of
illness estimates. RESULTS: Patients with Severe osteoporosis
incurred twice the amount of overall health care expenditures in
the study period compared to Non-Severe osteoporosis patients
and nearly three times that of the control group. Approximately
25% of the overall health care expenditures for the severe group
were osteoporosis-related expenditures, leading to the conclu-
sion that comorbid conditions in patients with severe osteo-
porosis contribute signiﬁcantly to overall health care costs. Some
of these comorbidity-related costs are likely due to pain-related
disorders, which occurred signiﬁcantly more frequently than in
the Non-Severe and Control cohorts. CONCLUSIONS: Osteo-
porosis-related expenditures, particularly those related to frac-
ture, were substantial. However, non-osteoporosis-related
expenditures to treat comorbid conditions constituted 75% of
the overall health care costs incurred in the year after an osteo-
porosis-related fracture and warrant further investigation.
POS4
COST-EFFECTIVENESS OF LONG-TERM HORMONE
REPLACEMENT THERAPY (ESTROGEN PLUS PROGESTIN) IN
HEALTHY POSTMENOPAUSAL WOMEN FOR OSTEOPOROSIS
PREVENTION
Yu YF, Hay JW,Yu AP
University of Southern California, Los Angeles, CA, USA
OBJECTIVES: To examine the cost and effectiveness of long-
term hormone replacement therapy (HRT) in healthy post-
menopausal women for preventing osteoporosis. Although HRT
has been widely used for osteoporosis prevention, previous
studies on its cost-effectiveness showed controversial results.
Recently, the Women’s Health Initiative (WHI) study found sig-
niﬁcant clinical risks with HRT. METHODS: From a societal
perspective, resource consumption, incidence rates and relative
risks were collected for the following diseases in HRT-treated
and HRT-naïve women: breast cancer, colorectal cancer, CHD,
stroke, pulmonary embolism, dementia, and bone fractures.
Besides the WHI results, cost, utility and other clinical data were
from published literature, CDC vital statistics databases, and
SEER cancer statistics. Using a 3% annual discount rate, pro-
jected lifetime costs and quality-adjusted life years (QALYs) were
estimated by DEALE and backward induction methods and com-
pared in women with HRT vs. without HRT for each age group
at 5-year intervals. RESULTS: Under the base case assumptions,
HRT increased average lifetime treatment costs ($20,753 for
non-HRT group vs. $31,941 for HRT group), and yet reduced
average discounted quality adjusted life expectancy (10.18 years
for non-HRT group vs. 5.87 years for HRT group), indicating
that HRT use is an inferior strategy. These negative results were
largely attributed to the net increased risks in breast cancer and
CHD due to HRT. As age increased from 50 to 90, the incre-
mental costs increased from $2221 to $18,988, and loss in
QALYs decreased from 10.8 to 0.44 years. The model results
were relatively insensitive to reasonable parameter changes.
CONCLUSIONS: For healthy postmenopausal women, long-
term HRT to prevent osteoporosis raises overall treatment costs
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and causes signiﬁcantly greater risks than beneﬁts. Even ignor-
ing alternative treatments for osteoporosis, not using HRT is a
dominant strategy in all age groups.
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ECONOMIC EVALUATION OF SHORT-TERM NON-VERTEBRAL
FRACTURE-RELATED COSTS AMONG OSTEOPOROSIS
TREATMENTS
Ohsfeldt RL1, Borisov NN2, Sheer RL2, Lindsay R3
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OBJECTIVES: The objective was to estimate direct medical costs
for non-vertebral fractures in the ﬁrst year of therapy among rise-
dronate, alendronate, and nasal calcitonin patients utilizing an
integrated administrative, medical and pharmacy claims data-
base. METHODS: A retrospective cohort study was conducted
among 5024 women and men (aged 45+) with a new prescrip-
tion for risedronate (5mg/day, or 30mg/week), alendronate (5
mg/day, 10mg/day, 35mg/week or 70mg/week), or nasal calci-
tonin (200I.U./day) between July 1, 2000, and June 30, 2001.
Non-vertebral fracture-related direct medical costs (inpatient
and outpatient care) were assessed for a 12-month period fol-
lowing initiation of the bisphosphonate or nasal calcitonin
therapy using 2003 Medicare fee schedule payments. Sites at
which a patient had a clinical fracture in the 6 months prior to
initiation of therapy were excluded from the analysis. RESULTS:
During the capture period patients were treated with alendronate
(74%), risedronate (13%), and nasal calcitonin (13%). There
were no baseline differences in age, gender or number of con-
comitant medications between risedronate and alendronate
patients. Nasal calcitonin patients, however, were signiﬁcantly
older and had higher concomitant medications use than both
risedronate and alendronate patients. Alendronate patients
incurred almost three times the fracture-related costs of rise-
dronate patients ($124 vs. $45, p = 0.019). Nasal calcitonin
patients incurred more than four times the fracture-related costs
of risedronate patients ($198 vs. $45, p = 0.028) in an adjusted
model. Alendronate patients did not have signiﬁcantly different
fracture-related costs than nasal calcitonin patients. CONCLU-
SIONS: Observed fracture-related costs among patients initiat-
ing risedronate therapy were lower than fracture-related costs
among patients of similar characteristics who initiated alen-
dronate therapy.
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TERIPARATIDE VERSUS BISPHOSPHONATES IN HIGH RISK
OSTEOPOROSIS PATIENTS: A DECISION MODEL ANALYSIS
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OBJECTIVES: Teriparatide has shown improved efﬁcacy in
increasing bone mineral density and decreasing nonvertebral
fractures in comparison to alendronate. The cost-effectiveness of
teriparatide over bisphosphonates has not been evaluated in the
VA Health System. This decision model seeks to evaluate all rel-
evant resource utilization and associated costs of osteoporosis
treatment with teriparatide compared to bisphosphonates to
determine the cost-effectiveness of each intervention in a high-
risk population. METHODS: The study was performed from the
government payer perspective. Resource utilization was ascer-
tained from published literature and relevant VA databases. Out-
comes data was reviewed and incorporated from published trials
and FDA reviews of teriparatide, alendronate, and risedronate
into an event targeted decision tree model. Pertinent utilization
rates and costs were captured including: emergency services, hos-
pitalization costs associated with fracture, osteoporosis drug
therapy costs, additional medication costs associated with frac-
ture, rehabilitation costs, outpatient visits, and nursing and home
health care costs. Outcome measurements include annualized
cost of treatment per vertebral and non-vertebral fractures over
a 2-year period. The decision tree was built with TreeAge®.
Crystal Ball® 2000 was used to perform the model analysis.
RESULTS: Compared to bisphosphonates, teriparatide demon-
strated fewer osteoporotic fractures and reduced total cost of
treatment. Although the VA medication acquisition cost of teri-
paratide is greater than ten times the cost of bisphosphonates,
this cost is offset by reduction in health care utilization costs.
The primary cost drivers were medications, hospitalizations,
rehabilitation, and nursing home costs. The total cost of treat-
ment for teriparatide was US$1,363,868 versus US$1,776,412
for bisphosphonates, with corresponding fracture rates of 11.35
and 18.19 per 100 patients, respectively. CONCLUSIONS: This
model suggests that teriparatide may be a cost effective therapy
in the treatment of high-risk osteoporosis patients from the per-
spective of the VA. The advantage of teriparatide over bisphos-
phonates may be attributed to the substantial differences in
fracture rates.
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Antiresoprtive therapies are used to prevent further fracture in
men and women with osteoporosis. However, patients with
severe osteoporosis may continue to fracture despite this therapy.
New trials have shown that teriparatide (Forteo) is efﬁcacious in
preventing new vertebral and non-vertebral fractures in patients
who have already experienced a vertebral fracture. OBJEC-
TIVES: This study aimed to assess the cost-effectiveness of teri-
paratide in preventing osteoporotic fractures in this population.
METHODS: A cost-utility model was developed to compare teri-
paratide with no therapy (placebo) in a population of osteo-
porotic patients with prior fracture. This model is a Markov
process estimated using Monte Carlo simulation. Relative efﬁ-
cacy assumptions in the model are based solely on the results of
randomised controlled trials (Neer et al., 2001), while the base-
line probability of fracture is derived from Australian epidemio-
logical data (Sanders et al., 1999). The cost-effectiveness of
teriparatide was assessed in terms of its impact in preventing new
vertebral and non-vertebral fractures in a cohort with at least
one prior radiologically conﬁrmed vertebral fracture and an
average age of 70 years. The model was designed so that the risk
of further vertebral fracture rises with each fracture. The model
ran for a ten-year period. Teriparatide is provided for 18 months,
after which patients have the choice of receiving a bispho-
sphonate or no additional therapy for a further 42 months.
RESULTS: Over the 10-year period, teriparatide is associated
with an increased cost of AUD$7337 ($US5503) and a gain of
0.4168 QALYs per patient compared with no treatment. Hence,
the incremental cost per QALY gained with teriparatide com-
pared with no treatment in this population was AUD$17,603
(US$13,202). Extensive sensitivity analyses indicated these
results were robust. CONCLUSIONS: Teriparatide is a cost-
effective therapy to reduce the risk of future fractures in men and
women with prior osteoporotic vertebral fracture.
